GENTAMICIN SULFATE description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

GENTAMICIN SULFATE

REMEDYREPACK INC.

GENTAMICIN SULFATEOphthalmic Solution, USP 0.3%


FULL PRESCRIBING INFORMATION: CONTENTS*




FULL PRESCRIBING INFORMATION

SPL UNCLASSIFIED

Sterile

 

GENTAMICIN SULFATE DESCRIPTION

GENTAMICIN SULFATE OPHTHALMIC SOLUTION, USP is a sterile, topical anti-infective agent for ophthalmic use. The active ingredient, gentamicin sulfate, is a water-soluble antibiotic of the aminoglycoside group.

Gentamicin is obtained from cultures of Micromonospora purpurea. It is a mixture of the sulfate salts of gentamicin C1, C2, and C1A. All three components appear to have similar antimicrobial activities. Gentamicin sulfate occurs as a white to buff powder and is soluble in water but insoluble in alcohol. The structural formula is as follows:

GENTAMICIN SULFATE

Each mL contains: Active: gentamicin sulfate equivalent to 3 mg (0.3%) gentamicin base. Preservative: benzalkonium chloride. Inactives: edetate disodium; polyvinyl alcohol 1.4%; purified water; sodium chloride; sodium phosphate, dibasic; and hydrochloric acid and/or sodium hydroxide to adjust the pH. The solution is an aqueous, buffered solution with a shelf life pH range of 6.5 to 7.5.

 

CLINICAL PHARMACOLOGY

Microbiology: Gentamicin sulfate is active in vitro against many strains of the following micro-organisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

 

INDICATIONS & USAGE

GENTAMICIN SULFATE OPHTHALMIC SOLUTION, USP is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

 

GENTAMICIN SULFATE CONTRAINDICATIONS

GENTAMICIN SULFATE OPHTHALMIC SOLUTION, USP is contraindicated in patients with known hypersensitivity to any of the components.

 

WARNINGS

NOT FOR INJECTION INTO THE EYE.

GENTAMICIN SULFATE OPHTHALMIC SOLUTION, USP is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.

 

PRECAUTIONS

Prolonged use of topical antibiotics may give rise to overgrowth of nonsusceptible microorganisms, including fungi. Bacterial resistance to gentamicin may also develop. If purulent discharge, inflammation or pain becomes aggravated, the patient should discontinue use of the medication and consult a physician.

If irritation or hypersensitivity to any component of the drug develops, the patient should discontinue use of this preparation and appropriate therapy should be instituted.

 

To avoid contamination, do not touch tip of container to the eye, eyelid or any surface.

 

There are no published carcinogenicity or impairment of fertility studies on gentamicin. Aminoglycoside antibiotics have been found to be non-mutagenic.

 

Pregnancy Category C: Gentamicin has been shown to depress body weights, kidney weights and median glomerular counts in newborn rats when administered systemically to pregnant rats in daily doses approximately 500 times the maximum recommended ophthalmic human dose. There are no adequate and well-controlled studies in pregnant women. Gentamicin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

 

Safety and effectiveness in neonates have not been established.

 

GENTAMICIN SULFATE ADVERSE REACTIONS

Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations.

The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects and conjunctival hyperemia. Other reactions which have occurred rarely are allergic reactions, thrombocytopenic purpura and hallucinations.

 

DOSAGE & ADMINISTRATION

Instill one or two drops into the affected eye(s) every four hours. In severe infections, dosage may be increased to as much as two drops every hour.

 

HOW SUPPLIED

GENTAMICIN SULFATE OPHTHALMIC SOLUTION, USP 0.3% is supplied sterile in white opaque LDPE plastic bottles and tips with white high impact polystyrene (HIPS) caps as follows:

             5 mL in 10 mL bottle – NDC 60758-188-05

Note: Store at or below 25°C (77°F). Avoid exposure to excessive heat (40°C/104°F or above).

Rx only

Revised January 2003

© 2004 PACIFIC PHARMA
Irvine, CA 92612 U.S.A.

GENTAMICIN SULFATE
71759PY10P

 

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION

DRUG: GENTAMICIN SULFATE


GENERIC: gentamicin sulfate


DOSAGE: SOLUTION/ DROPS


ADMINSTRATION: OPHTHALMIC


NDC: 52125-461-57


ACTIVE INGREDIENT(S):

  • gentamicin sulfate 3mg in 1mL


INACTIVE INGREDIENT(S):

  • benzalkonium chloride
  • edetate disodium
  • hydrochloric acid
  • sodium phosphate, dibasic
  • polyvinyl alcohol
  • sodium chloride
  • sodium hydroxide
  • water


PACKAGING: 5 mL in 1 BOTTLE, DROPPER




GENTAMICIN SULFATE

GENTAMICIN SULFATE

>

GENTAMICIN SULFATE

gentamicin sulfate SOLUTION/ DROPS

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:52125-461(NDC:60758-188)
Route of Administration OPHTHALMIC DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
Gentamicin Sulfate GENTAMICIN 3 mg

Inactive Ingredients

Ingredient Name Strength
benzalkonium chloride
EDETATE DISODIUM
HYDROCHLORIC ACID
SODIUM PHOSPHATE, DIBASIC
POLYVINYL ALCOHOL
SODIUM CHLORIDE
SODIUM HYDROXIDE
water

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:52125-461-57 5 in 1 BOTTLE, DROPPER

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA062452 2013-12-05


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.